Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SARS-CoV-2 (COVID-19) Severe Pneumonia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04516928
What this trial is testing

Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel

Who this might be right for
SARS-CoV InfectionCovid19
Direction Centrale du Service de Santé des Armées 392
Not applicableStudy completedNCT04912700
What this trial is testing

The Impact of Vaccination on Severity of Illness in COVID-19

Who this might be right for
Covid19
Corewell Health East 11,834
Large-scale testing (Phase 3)Study completedNCT04501978
What this trial is testing

ACTIV-3: Therapeutics for Inpatients With COVID-19

Who this might be right for
Covid19
National Institute of Allergy and Infectious Diseases (NIAID) 2,753
Testing effectiveness (Phase 2)Ended earlyNCT04511650
What this trial is testing

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

Who this might be right for
COVID-19Acute Respiratory Distress Syndrome (ARDS)
EyePoint Pharmaceuticals, Inc. 31
Post-approval studies (Phase 4)Active Not RecruitingNCT07266558
What this trial is testing

Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Who this might be right for
SARS-CoV-2
ModernaTX, Inc. 30,000
Not applicableStudy completedNCT04367740
What this trial is testing

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

Who this might be right for
Asymptomatic ConditionInfection ViralCoronavirus Infections+5 more
University of North Carolina, Chapel Hill 6,313
Testing effectiveness (Phase 2)Ended earlyNCT04342897
What this trial is testing

LY3127804 in Participants With COVID-19

Who this might be right for
COVID-19Pneumonia
Eli Lilly and Company 95
Not applicableUnknownNCT05767853
What this trial is testing

Multiparametric Assessment of Peripheral Blood and Tissue Myeloid Cells. Phenotype for Precision Medicine in Patients With SARS-Cov-2 Infection

Who this might be right for
COVID-19 Pneumonia
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 30
Not applicableStudy completedNCT04490850
What this trial is testing

COVID-19 Seroprevalence Study in French Guiana

Who this might be right for
Coronavirus InfectionSevere Acute Respiratory SyndromeSARS-CoV Infection+1 more
Institut Pasteur 3,541
Testing effectiveness (Phase 2)Study completedNCT04419025
What this trial is testing

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Who this might be right for
COVIDSars-CoV2SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere+1 more
Cambridge Health Alliance 165
Testing effectiveness (Phase 2)Ended earlyNCT04432298
What this trial is testing

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

Who this might be right for
COVID-19
Kyntra Bio 22
Testing effectiveness (Phase 2)Study completedNCT04563208
What this trial is testing

Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19

Who this might be right for
Covid19SARS-CoV Infection
University of Witwatersrand, South Africa 80
Not applicableStudy completedNCT04745416
What this trial is testing

Clinical Characteristics of Patients With Leukemia and COVID-19

Who this might be right for
Leukemia, AcuteCovid19Leukemia, Lymphoblastic
Hospital General de Mexico 30
Not applicableStudy completedNCT04584658
What this trial is testing

Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)

Who this might be right for
DysphagiaDysphoniaSubglottic Stenosis+7 more
Cambridge University Hospitals NHS Foundation Trust 50
Not applicableWithdrawnNCT04403035
What this trial is testing

Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19

Who this might be right for
Covid-19
Henry Ford Health System
Large-scale testing (Phase 3)Study completedNCT06729606
What this trial is testing

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Who this might be right for
Covid19
National Institute of Allergy and Infectious Diseases (NIAID) 471
Testing effectiveness (Phase 2)Study completedNCT04551898
What this trial is testing

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Who this might be right for
Covid19
BeiGene 181
Not applicableStudy completedNCT07466524
What this trial is testing

SuPAR Michigan M2C2 Heterogeneity Validation Cohort Study

Who this might be right for
COVID-19Severe Respiratory Distress SyndromeAcute Respiratory Distress Syndrome
ViroGates A/S 367
Not applicableUnknownNCT04948242
What this trial is testing

Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

Who this might be right for
SARS-CoV2 Infection
Hospital Universitari Joan XXIII de Tarragona. 5,000
Testing effectiveness (Phase 2)Study completedNCT04357782
What this trial is testing

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

Who this might be right for
COVID-19Hypoxia
Hunter Holmes Mcguire Veteran Affairs Medical Center 20
Next Page